Last $11.35 USD
Change Today +0.39 / 3.56%
Volume 717.6K
CEMP On Other Exchanges
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $15.39
52 Week Low
04/15/14 - $8.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEMPRA INC (CEMP)

cempra inc (CEMP) Related Businessweek News

No Related Businessweek News Found

cempra inc (CEMP) Details

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

38 Employees
Last Reported Date: 02/28/14
Founded in 2005

cempra inc (CEMP) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $447.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $292.6K
Compensation as of Fiscal Year 2013.

cempra inc (CEMP) Key Developments

Cempra, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 11:00 AM

Cempra, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 11:00 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Prabhavathi B. Fernandes, Founder, Chief Executive Officer, President and Director.

Cempra Initiates Phase 3 Clinical Trial in Patients with Uncomplicated Gonorrhea Infection

Cempra, Inc. announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections. The trial is being conducted in Australia and the U.S. and will enroll approximately 300 patients in a randomized 2-arm study with a single oral dose of 1000 mg of solithromycin compared with the standard of care, 500 mg of ceftriaxone administered intramuscularly and 1000 mg of oral azithromycin.

Cempra, Inc. - Analyst/Investor Day

Cempra, Inc. - Analyst/Investor Day


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $11.35 USD +0.39

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies

Industry Analysis


Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.3x
Price/Book 9.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at